Impedimed Earnings Estimate

IPD Stock   0.05  0  2.00%   
By analyzing Impedimed's earnings estimates, investors can diagnose different trends across Impedimed's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Impedimed is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Yuan Drop
 
Covid
Impedimed is projected to generate -0.00105 in earnings per share on the 30th of June 2026. Impedimed earnings estimates module stress-tests analyst consensus about projected Impedimed EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Impedimed, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Impedimed's earnings estimates, investors can diagnose different trends across Impedimed's analyst sentiment over time as well as compare current estimates against different timeframes. Gross Profit is likely to gain to about 9.5 M in 2024
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Impedimed. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Impedimed Earnings per Share Projection vs Actual

About Impedimed Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Impedimed earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Impedimed estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Impedimed fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-331 M-314.4 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Impedimed Stock Analysis

When running Impedimed's price analysis, check to measure Impedimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Impedimed is operating at the current time. Most of Impedimed's value examination focuses on studying past and present price action to predict the probability of Impedimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Impedimed's price. Additionally, you may evaluate how the addition of Impedimed to your portfolios can decrease your overall portfolio volatility.